Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In?
Natera (NTRA) has drawn fresh investor attention after a series of partnerships and approvals, including new Phase 3 trial collaborations and regulatory clearance for its Signatera test in Japan for colorectal cancer. See our latest analysis for Nate...